Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NEXTAR - NEXavar as First TARgeted Treatment for Patients With Advanced Renal Cell Carcinoma

Next Previous
Search
Trial Profile

NEXTAR - NEXavar as First TARgeted Treatment for Patients With Advanced Renal Cell Carcinoma

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms NEXTAR
  • Sponsors Bayer

Most Recent Events

  • 28 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 03 Jul 2013 New source identified and integrated (German Clinical Trials Register: DRKS00004148).
  • 01 Jul 2013 Planned end date changed from 1 Mar 2015 to 1 Mar 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top